Navigation Links
Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
Date:6/18/2008

s of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, Merrill Lynch and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

Trofile is a trademark of Monogram Biosciences, Inc.

contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624 4576 Tel: 415 677 2700

amerriweather@ jeremiah.hall@


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Monogram Announces First Medicare Payment for Trofile(TM)
2. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
3. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
6. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
9. Anaptys Biosciences Raises Over $33 Million in Series B Financing
10. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
11. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... (PRWEB) July 24, 2014 Vulnerable ... and low-income households are disproportionately affected by food ... safety net in the United States, according to ... Section 743 of the Consolidated Appropriations Act, 2014 ... Agriculture's Food and Nutrition Service (FNS) to contract ...
(Date:7/24/2014)... In a July 9th article in the ... Lotus Blossom Consulting LLC , was quoted in a ... to Cut the High Cost of Infertility . Her advice ... to maximize your chance of success from the first attempt.” ... , “I am always happy to talk with the ...
(Date:7/24/2014)... the risk for head and neck cancer (HNC). Evidence suggests ... the risk of HNC in patients with DM has not ... sixth most common type of cancer. It accounts for about ... new cancer cases and 350,000 cancer deaths worldwide each year. ... to examine the risk of HNC in patients with DM. ...
(Date:7/24/2014)... Kan. (PRWEB) July 24, 2014 ... announces that it has achieved certification for compliance ... tested and verified by the DoD Information Assurance ... Vendor Neutral Archive, identified within the DoD as ... Authority to Operate designation from the U.S. Army ...
(Date:7/24/2014)... Researchers at Le Bonheur Children,s Hospital and the University ... clinical trial of a new drug shown to safely ... adult volunteers intranasally infected with respiratory syncytial virus (RSV). ... tract infections in young children in the United States ... labs of Infectious Disease Specialist John DeVincenzo, MD. DeVincenzo,s ...
Breaking Medicine News(10 mins):Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 3Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:RSV research breakthrough to help infected children 2
... been forced to revise statements made by Pope Benedict XVI ... Cameroon on March 17, the pope claimed that condom use ... pope,s comments on the Vatican,s Web site altered the comment ... of Catholics for Choice, welcomed the change as a sign ...
... hypertension, obesity, study found , , WEDNESDAY, March 18 (HealthDay News) ... than whites, a long-running study shows. , "What we found ... and it is not a rare occurrence," said Dr. Kirsten ... issue of the New England Journal of Medicine . ...
... fees to researchers and clinicians to identify study participants ... many medical schools fail to address this conflict of ... , Leslie Wolf, an associate professor of law at ... the Web sites of 117 medical schools that received ...
... finds risk of disease recurrence, death nearly twice that ... -- Obese pancreatic cancer patients are more likely than ... treat their cancer, say U.S. researchers. , "We ... 35) who were at 12-fold increased risk of lymph ...
... formalize a partnership to prevent the spread of HIV ... Russia.WASHINGTON, March 18 /PRNewswire-USNewswire/ -- ... the spread of HIV and increase access to HIV ... youth in St. Petersburg, Russia was announced by the ...
... chronic conditions most in need of help with ... survey of Californians with chronic conditions, commissioned by ... regarding the prevalence of and lack of resources ... due to the economic downturn, many of these ...
Cached Medicine News:Health News:Pope Not Infallible on Condoms 2Health News:High Rate of Early Heart Failure Seen in Blacks 2Health News:High Rate of Early Heart Failure Seen in Blacks 3Health News:Conflicts of interest in clinical research 2Health News:Obesity Tied to Poor Pancreatic Cancer Surgery Outcomes 2Health News:Partnership to Prevent HIV Among Vulnerable Russian Youth 2Health News:Partnership to Prevent HIV Among Vulnerable Russian Youth 3Health News:Many Young Adults Struggle to Manage Multiple Chronic Conditions 2Health News:Many Young Adults Struggle to Manage Multiple Chronic Conditions 3Health News:Many Young Adults Struggle to Manage Multiple Chronic Conditions 4
(Date:7/24/2014)... , July 24, 2014  IRIDEX Corporation (NASDAQ: ... release its second quarter 2014 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, July ... quarter and other business developments. Interested parties ...
(Date:7/24/2014)... VANCOUVER, British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today ... the company,s fiscal year from December 31 to June 30. ... before September 30, 2014. Jeffrey Bacha , ... year end is an important step in achieving our goal ...
(Date:7/24/2014)... , July 24, 2014  Kinex Pharmaceuticals announced the ... the Company,s KX2-391 Ointment for the commencement of a ... the Company,s third IND to be allowed by the ... KX2-391 is a synthetic, orally active and highly selective ... KX2-391 promotes the induction of p53, G2/M arrest of ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... trial delivery time and ensure faster access to client ... ... DATATRAK International,Inc. (Nasdaq: DATA ), a technology and services company focused ... options, flexibility and efficiency for end-users with the,DATATRAK eClinical(TM) 2008 Q1 Release., ...
... Alfacell Corporation,(Nasdaq: ACEL ) today announced that 311 ... clinical trial of its lead compound,ONCONASE, for the treatment ... Phase IIIb clinical trial was,closed on Sept. 30, 2007. ... In accordance with the statistical plan for the ...
Cached Medicine Technology:DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0 2DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0 3DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0 4DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0 5Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program 2
Disposable tracheostomy care tray....
Disposable tracheostomy care tray....
... the Right Solution For Your Tracheostomy Care ... care tray features the latest components for ... infection control task. Designed by clinicians, these ... of each patient and caregiver. All of ...
... For Your Tracheostomy Care Needs, ,Each ... the latest components for efficient and convenient ... Designed by clinicians, these latex-free trays provide ... and caregiver. All of our trays also ...
Medicine Products: